News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,856 Results
Type
Article (127)
Company Profile (1)
Press Release (2728)
Section
Business (629)
Career Advice (5)
Deals (103)
Drug Delivery (1)
Drug Development (247)
FDA (37)
Job Trends (30)
News (997)
Policy (81)
Tag
Academia (6)
Alliances (212)
Alzheimer's disease (8)
Antibody-drug conjugate (ADC) (12)
Approvals (38)
Artificial intelligence (1)
Automation (1)
Best Places to Work (19)
Biosimilars (18)
Biotechnology (3)
Brain cancer (1)
Cancer (13)
Cardiovascular disease (1)
Career advice (5)
Career pathing (1)
Cell therapy (3)
Clinical research (213)
Collaboration (14)
COVID-19 (12)
C-suite (1)
Data (12)
Diabetes (1)
Diagnostics (11)
Digital health (1)
Earnings (229)
Events (930)
Executive appointments (2)
FDA (49)
Funding (3)
Gene therapy (1)
GLP-1 (2)
Government (6)
Guidances (4)
Healthcare (81)
Immunology and inflammation (9)
Infectious disease (13)
Inflammatory bowel disease (1)
IPO (50)
Job creations (8)
Job search strategy (3)
JPM (1)
Layoffs (2)
Leadership (1)
Legal (15)
Machine learning (1)
Manufacturing (20)
Medical device (26)
Medtech (26)
Mergers & acquisitions (59)
Metabolic disorders (1)
Multiple sclerosis (1)
Neuroscience (9)
NextGen: Class of 2026 (12)
Non-profit (6)
Now hiring (2)
Opinion (1)
Partnered (2)
Patents (2)
Patient recruitment (1)
People (176)
Phase 1 (65)
Phase 2 (104)
Phase 3 (64)
Pipeline (32)
Postmarket research (6)
Preclinical (26)
Prostate cancer (2)
Radiopharmaceuticals (3)
Rare diseases (1)
Real estate (28)
Regulatory (72)
Reports (3)
Research institute (10)
Resumes & cover letters (1)
Rett syndrome (1)
Startups (13)
Supply chain (1)
Tariffs (1)
Vaccines (6)
Date
Last 30 days (5)
Last 365 days (162)
2026 (5)
2025 (165)
2024 (193)
2023 (161)
2022 (524)
2021 (422)
2020 (224)
2019 (119)
2018 (94)
2017 (108)
2016 (110)
2015 (108)
2014 (80)
2013 (91)
2012 (64)
2011 (105)
2010 (73)
Location
Africa (2)
Alabama (1)
Arizona (1)
Asia (232)
Australia (29)
California (54)
Canada (16)
China (5)
Europe (380)
Florida (23)
Idaho (2)
India (10)
Indiana (2)
Maryland (5)
Massachusetts (27)
Minnesota (1)
Missouri (2)
Nevada (1)
New Jersey (22)
New York (8)
North Carolina (6)
Northern California (17)
Pennsylvania (15)
South America (8)
Southern California (20)
Texas (7)
United States (177)
Utah (1)
Virginia (1)
Washington State (2)
Wisconsin (1)
2,856 Results for "biocon limited.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
December 8, 2025
·
6 min read
Press Releases
Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®
October 23, 2025
·
8 min read
Press Releases
Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
September 11, 2025
·
4 min read
Press Releases
Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
October 2, 2025
·
13 min read
Press Releases
Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
October 16, 2025
·
9 min read
Press Releases
Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
September 18, 2025
·
13 min read
Press Releases
Biocon Biologics’ Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases
September 18, 2025
·
7 min read
Press Releases
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
July 16, 2025
·
8 min read
Press Releases
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
April 16, 2025
·
7 min read
Press Releases
Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
May 5, 2025
·
8 min read
1 of 286
Next
